Loading the company…
Loading the company…
In the last ten years FDA made 5 decisions for Urotronic (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2025 (2). The latest was on 2025-12-15.
| Family | Decisions on record |
|---|---|
| BPH procedures | 5 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2025-12-15 | PMA | P220029-S003 | Optilume BPH Catheter System · Postapproval Study Protocol |
| 2025-12-12 | PMA | P220029-S004 | Optilume BPH Catheter System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2024-08-15 | PMA | P220029-S002 | Optilume BPH Catheter System · Change Design/Components/Specifications/Material |
| 2023-08-25 | PMA | P220029-S001 | Optilume BPH Catheter System · Postapproval Study Protocol |
| 2023-06-30 | PMA | P220029 | Optilume BPH Catheter System · Drug coated prostatic dilation catheter for benign prostatic hyperplasia |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Urotronic.